Internal Server Error

Carmot - About the company

Carmot is an acquired company based in Berkeley (United States), founded in 2008 by Stig Hansen and Daniel Erlanson. It operates as a Developer of disease-modifying therapies to treat metabolic diseases. Carmot has raised $386M in funding from investors like The Column Group, Horizons Ventures and Amgen, with last known valuation of $*****. The company has 420 active competitors, including 164 funded and 67 that have exited. Its top competitors include companies like Sana Biotechnology, Adocia and Kailera.

Company Details

Developer of disease-modifying therapies to treat metabolic diseases. The company is pioneering a drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics for metabolic diseases including obesity and diabetes. The company has three clinical candidates including CT-388, CT-868, and CT-996.
Social
X
Email ID
*****@carmot.us
Phone Number
+1 **********
Part Of
Key Metrics
Founded Year
2008
Location
Berkeley, United States
Stage
Acquired
Total Funding
$386M in 16 rounds
Latest Funding Round
Last Known Valuation
$***** as on May 25, 2023
Ranked
Employee Count
4 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Roche (Dec 04, 2023)

Carmot's acquisition details

Carmot got acquired by Roche on Dec 04, 2023 at an acquisition amount of $*****.
Click here to take a look at Carmot's acquisition in detail
Sign up to download Carmot's company profile

Carmot's funding and investors

Carmot has raised a total funding of $386M over 16 rounds. Its first funding round was on Oct 22, 2009. Its latest funding round was a Series E round on May 25, 2023 for $*****. 13 investors participated in its latest round. Carmot has 18 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Carmot:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
May 25, 2023
1300087
Series E
9824545
6285251
3529322
7875267
Jul 26, 2022
5553161
Series D
9186090
4608824
4150911
Sep 30, 2020
3834003
Series C
4171100
3474363
lockAccess funding benchmarks and valuations. Sign up today!

Carmot's founders and board of directors

Founder? Claim Profile
The founders of Carmot are Stig Hansen and Daniel Erlanson. Heather Turner is the CEO of Carmot.
Here are the details of Carmot's key team members:

Carmot's employee count trend

Carmot has 4 employees as of Sep 26. Here is Carmot's employee count trend over the years:
Employee count trend for Carmot
lockUncover Carmot's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Carmot's Competitors and alternates

Top competitors of Carmot include Sana Biotechnology, Adocia and Kailera. Here is the list of Top 10 competitors of Carmot, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Sana Biotechnology
Sana Biotechnology
2018, Seattle (United States), Public
Developer of engineered cell therapies for treating various human diseases
$821M
74/100
2nd
Logo for Adocia
Adocia
2005, Lyon (France), Public
Developer of therapeutics for the treatment of diabetes and obesity
$26M
69/100
3rd
Logo for Kailera
Kailera
2024, Waltham (United States), Public
Developer of therapies for treating obesity and related conditions
$1B
65/100
4th
Logo for Structure
Structure
2017, San Francisco (United States), Public
Developer of oral small molecule drugs for chronic diseases
$191M
65/100
5th
Logo for Assembly Biosciences
Assembly Biosciences
2005, New York City (United States), Public
Developing novel antivirals to treat serious viral diseases
$700K
65/100
6th
Logo for Cellino
Cellino
2017, Cambridge (United States), Series A
Developer of autologous cell therapies
$125M
65/100
7th
Logo for Quell
Quell
2019, London (United Kingdom), Series B
Developer of engineered regulatory T cell therapies for immune diseases
$344M
64/100
8th
Logo for Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
1995, The Woodlands (United States), Public
Developer of small molecule drugs for diffrent health diseases
-
64/100
9th
Logo for Rezolute
Rezolute
2012, Denver (United States), Public
Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)
-
64/100
10th
Logo for Kriya Therapeutics
Kriya Therapeutics
2012, Redwood City (United States), Series D
Developer of therapeutic solutions for the treatment of diabetes
$938M
64/100
52nd
Logo for Carmot
Carmot
2008, Berkeley (United States), Acquired
Developer of disease-modifying therapies to treat metabolic diseases
$386M
59/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Carmot's competitors? Click here to see the top ones

Carmot's Investments and acquisitions

Carmot has made no investments or acquisitions yet.

Reports related to Carmot

Here is the latest report on Carmot's sector:

News related to Carmot

lockFilter this list
Media has covered Carmot for a total of 5 events in the last 1 year, 4 of them have been about company updates.
•
Roche Completes $2.7B Acquisition of Carmot TherapeuticsContract Pharma•Jul 29, 2024•Roche, Carmot
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Carmot

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford